These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy. Dosi C; Tozzo A; Masson R Pediatr Neurol; 2022 Jun; 131():23-24. PubMed ID: 35462108 [No Abstract] [Full Text] [Related]
8. The 4-Copy Conundrum in the Treatment of Infants with Spinal Muscular Atrophy. Deng S; Lee BH; Ciafaloni E; Mackenzie SJ Ann Neurol; 2022 Jun; 91(6):891. PubMed ID: 35338521 [No Abstract] [Full Text] [Related]
10. Spinal and bulbar muscular atrophy without tongue atrophy. Sugawara M; Kato K; Watanabe S; Toyoshima I Eur Neurol; 2001; 45(3):185-6. PubMed ID: 11306865 [No Abstract] [Full Text] [Related]
11. Reply to: The 4-Copy Conundrum in the Treatment of Infants with Spinal Muscular Atrophy. Yeo CJJ; Simmons Z; De Vivo DC; Darras BT Ann Neurol; 2022 Jun; 91(6):892. PubMed ID: 35332578 [No Abstract] [Full Text] [Related]
12. Translating fatigability in spinal muscular atrophy to clinical trials and management. Yeo CJJ; Darras BT Muscle Nerve; 2023 Jul; 68(1):6-7. PubMed ID: 37086214 [No Abstract] [Full Text] [Related]
13. Gene therapy for spinal muscular atrophy: hope and caution. Goemans N Lancet Neurol; 2021 Apr; 20(4):251-252. PubMed ID: 33743228 [No Abstract] [Full Text] [Related]
14. The genetics of the spinal muscular atrophies. Baraitser M Prog Clin Biol Res; 1989; 306():75-84. PubMed ID: 2662214 [No Abstract] [Full Text] [Related]
15. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective. Oskoui M; Gonorazky H; McMillan HJ; Dowling JJ; Amin R; Gagnon C; Selby K Can J Neurol Sci; 2022 May; 49(3):398-401. PubMed ID: 34082851 [No Abstract] [Full Text] [Related]
16. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy. Schön M; Domingues S; de Carvalho M; Oliveira Santos M Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532 [No Abstract] [Full Text] [Related]
17. Spinal Muscular Atrophy Type 1 With Exon 8 Deletion and Bilateral Optic Atrophy. Behera B; Kumar A Indian Pediatr; 2020 Dec; 57(12):1191. PubMed ID: 33318336 [No Abstract] [Full Text] [Related]
18. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1. Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256 [No Abstract] [Full Text] [Related]
19. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Melki J; Lefebvre S; Burglen L; Burlet P; Clermont O; Millasseau P; Reboullet S; Bénichou B; Zeviani M; Le Paslier D Science; 1994 Jun; 264(5164):1474-7. PubMed ID: 7910982 [TBL] [Abstract][Full Text] [Related]
20. New results for risdiplam in spinal muscular atrophy. Iannaccone ST Lancet Neurol; 2022 Dec; 21(12):1065-1066. PubMed ID: 36244363 [No Abstract] [Full Text] [Related] [Next] [New Search]